| Kevin M Longshaw, MD | |
|
9528 Webb Chapel Rd, Dallas, TX 75220-4938 | |
| (214) 357-7311 | |
| (214) 352-8150 |
| Full Name | Kevin M Longshaw |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 9528 Webb Chapel Rd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013942374 | NPI | - | NPPES |
| 043606502 | Medicaid | TX | |
| 043606503 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | K1242 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Legacy Healthcare Services Inc | 2163339722 | 2654 |
| Texas Health Physicians Group | 4385535954 | 1182 |
News Archive
Researchers studying cancer and other invasive diseases rely on high-resolution imaging to see tumors and other activity deep within the body's tissues. Using a new high-speed, high-resolution imaging method, Lihong Wang, PhD, and his team at Washington University in St. Louis were able to see blood flow, blood oxygenation, oxygen metabolism and other functions inside a living mouse brain at faster rates than ever before.
The Detroit News: "A Michigan Healthcare Freedom Act allowing Michiganians to opt out of the federal healthcare bill will be introduced when the Legislature resumes session July 21." The proposal was announced Tuesday, after a petition drive against the federal healthcare plan fell short. The grassroots organizers of that effort "hoped to get a question on the November election ballot asking Michigan voters to decide if they want to opt out of the federal health care overhaul, but they failed to collect enough petition signatures by Monday's deadline".
Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult.
Human Pheromone Sciences, Inc. today announced results for the first quarter ended March 31, 2010. Net revenues of $185,000 represented a 12% increase from the revenues of $165,000 in the prior year period, and resulted in a net loss of $98,000 ($.02 per share) as compared with net loss of $181,000 ($.04 per share) for the same period in 2009.
Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).
› Verified 6 days ago
| Entity Name | Texas Health Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174573596 PECOS PAC ID: 4385535954 Enrollment ID: O20040323000759 |
News Archive
Researchers studying cancer and other invasive diseases rely on high-resolution imaging to see tumors and other activity deep within the body's tissues. Using a new high-speed, high-resolution imaging method, Lihong Wang, PhD, and his team at Washington University in St. Louis were able to see blood flow, blood oxygenation, oxygen metabolism and other functions inside a living mouse brain at faster rates than ever before.
The Detroit News: "A Michigan Healthcare Freedom Act allowing Michiganians to opt out of the federal healthcare bill will be introduced when the Legislature resumes session July 21." The proposal was announced Tuesday, after a petition drive against the federal healthcare plan fell short. The grassroots organizers of that effort "hoped to get a question on the November election ballot asking Michigan voters to decide if they want to opt out of the federal health care overhaul, but they failed to collect enough petition signatures by Monday's deadline".
Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult.
Human Pheromone Sciences, Inc. today announced results for the first quarter ended March 31, 2010. Net revenues of $185,000 represented a 12% increase from the revenues of $165,000 in the prior year period, and resulted in a net loss of $98,000 ($.02 per share) as compared with net loss of $181,000 ($.04 per share) for the same period in 2009.
Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin M Longshaw, MD 9528 Webb Chapel Rd, Dallas, TX 75220-4938 Ph: (214) 357-7311 | Kevin M Longshaw, MD 9528 Webb Chapel Rd, Dallas, TX 75220-4938 Ph: (214) 357-7311 |
News Archive
Researchers studying cancer and other invasive diseases rely on high-resolution imaging to see tumors and other activity deep within the body's tissues. Using a new high-speed, high-resolution imaging method, Lihong Wang, PhD, and his team at Washington University in St. Louis were able to see blood flow, blood oxygenation, oxygen metabolism and other functions inside a living mouse brain at faster rates than ever before.
The Detroit News: "A Michigan Healthcare Freedom Act allowing Michiganians to opt out of the federal healthcare bill will be introduced when the Legislature resumes session July 21." The proposal was announced Tuesday, after a petition drive against the federal healthcare plan fell short. The grassroots organizers of that effort "hoped to get a question on the November election ballot asking Michigan voters to decide if they want to opt out of the federal health care overhaul, but they failed to collect enough petition signatures by Monday's deadline".
Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult.
Human Pheromone Sciences, Inc. today announced results for the first quarter ended March 31, 2010. Net revenues of $185,000 represented a 12% increase from the revenues of $165,000 in the prior year period, and resulted in a net loss of $98,000 ($.02 per share) as compared with net loss of $181,000 ($.04 per share) for the same period in 2009.
Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).
› Verified 6 days ago
Dr. Juan F Quiroz, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4811a Columbia Ave, Dallas, TX 75226 Phone: 214-823-5590 Fax: 214-823-6638 | |
Dr. Michelle Dobbs, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 6333 E Mockingbird Ln, Suite 126, Dallas, TX 75214 Phone: 214-826-6005 | |
Howard J Huntzinger, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9250 Amberton Pkwy, Dallas, TX 75243 Phone: 682-236-3656 | |
Robert J Dimeff, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8081 Walnut Hill Ln, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 | |
Pardeep K Shori, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7012 La Vista Dr, Dallas, TX 75214 Phone: 817-564-5761 | |
Mary Elizabeth Wilcox Smith, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2921 Fairmount St, Dallas, TX 75201 Phone: 214-742-9310 | |
Elizabeth Chapek, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 6760 Abrams Rd, Suite 203, Dallas, TX 75231 Phone: 214-341-8742 |